{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:41:53Z","timestamp":1792676513845,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neurol.2026.04.001","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T11:14:26Z","timestamp":1776683666000},"page":"381-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["New immunotherapies for multiple sclerosis (MS): A comprehensive review"],"prefix":"10.1016","volume":"182","author":[{"given":"X.","family":"Ayrignac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2026.04.001_bib0325","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2026.04.001_bib0330","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41582-024-01006-1","article-title":"Assessing disease progression and treatment response in progressive multiple sclerosis","volume":"20","author":"Comi","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0335","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","article-title":"Standardized definition of Progression Independent of Relapse Activity (PIRA) in relapsing-remitting multiple sclerosis","volume":"82","author":"M\u00fcller","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0340","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","article-title":"Secondary progressive multiple sclerosis","volume":"97","author":"Cree","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.04.001_bib0345","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0350","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1038\/s41591-025-03901-6","article-title":"AI-driven reclassification of multiple sclerosis progression","volume":"31","author":"Ganjgahi","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2026.04.001_bib0355","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.04.001_bib0360","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/CPJ.0000000000001045","article-title":"Multiple sclerosis phenotypes as a continuum","volume":"11","author":"Vollmer","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.neurol.2026.04.001_bib0365","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0370","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/WCO.0000000000000818","article-title":"Mechanisms underlying progression in multiple sclerosis","volume":"33","author":"Absinta","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0375","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","article-title":"Multiple sclerosis: mechanisms and immunotherapy","volume":"97","author":"Baecher-Allan","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2026.04.001_bib0380","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0385","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs. relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0390","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"San Francisco MS-EPIC Team","year":"2019","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0395","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2026.04.001_bib0400","doi-asserted-by":"crossref","first-page":"e210142","DOI":"10.1212\/WNL.0000000000210142","article-title":"Long-term treatment with ocrelizumab in patients with early-stage relapsing MS","volume":"104","author":"Cerqueira","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.04.001_bib0405","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0410","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.04.001_bib0415","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41582-020-00446-9","article-title":"Facing the urgency of therapies for progressive MS\u00a0\u2014\u00a0a Progressive MS Alliance proposal","volume":"17","author":"Dangond","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0420","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.27270","article-title":"New horizons for multiple sclerosis therapy: 2025 and beyond","volume":"98","author":"Sabatino","year":"2025","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0425","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the \u2018real MS\u2019","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2026.04.001_bib0430","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41582-023-00801-6","article-title":"Inflammation in multiple sclerosis: consequences for remyelination and disease progression","volume":"19","author":"Klotz","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0435","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1474-4422(18)30451-4","article-title":"Association between pathological and MRI findings in multiple sclerosis","volume":"18","author":"Filippi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0440","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","article-title":"B cells in autoimmune and neurodegenerative central nervous system diseases","volume":"20","author":"Sabatino","year":"2019","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.neurol.2026.04.001_bib0445","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029025","article-title":"Effector T cells in multiple sclerosis","volume":"8","author":"Kaskow","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.neurol.2026.04.001_bib0450","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/ncpneuro0832","article-title":"The role of regulatory T cells in multiple sclerosis","volume":"4","author":"Zozulya","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0455","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0460","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2023.03.008","article-title":"Multiple sclerosis: neuroimmune crosstalk and therapeutic targeting","volume":"186","author":"Charabati","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2026.04.001_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.015","article-title":"The roles of macrophages and microglia in multiple sclerosis and experimental autoimmune encephalomyelitis","volume":"318","author":"Chu","year":"2018","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0470","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis\u00a0\u2014\u00a0from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0475","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00415-025-12917-4","article-title":"Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion","volume":"272","author":"Filippi","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0480","doi-asserted-by":"crossref","first-page":"104789","DOI":"10.1016\/j.ebiom.2023.104789","article-title":"Cross-talk between B cells, microglia and macrophages, and implications to central nervous system compartmentalized inflammation and progressive multiple sclerosis","volume":"96","author":"Touil","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neurol.2026.04.001_bib0485","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1016\/j.neuron.2022.06.023","article-title":"Microglia in multiple sclerosis: protectors turn destroyers","volume":"110","author":"Yong","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2026.04.001_bib0490","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s12026-007-8009-6","article-title":"B-cells and humoral immunity in multiple sclerosis. Implications for therapy","volume":"40","author":"Oh","year":"2008","journal-title":"Immunol Res"},{"key":"10.1016\/j.neurol.2026.04.001_bib0495","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fimmu.2018.00217","article-title":"The role of astrocytes in multiple sclerosis","volume":"9","author":"Ponath","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0500","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.neurol.2026.04.001_bib0505","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/1352458520907901","article-title":"Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors","volume":"26","author":"Jacobs","year":"2020","journal-title":"Mult Scler J"},{"key":"10.1016\/j.neurol.2026.04.001_bib0510","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","article-title":"Multiple sclerosis: molecular pathogenesis and therapeutic intervention","volume":"10","author":"Boutitah-Benyaich","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.neurol.2026.04.001_bib0515","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1007\/s10072-025-08392-4","article-title":"Therapeutic evaluation of immunomodulators and immunosuppressants in progressive multiple sclerosis: summary of a Cochrane systematic review","volume":"46","author":"Dang","year":"2025","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2026.04.001_bib0520","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2026.04.001_bib0525","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41582-019-0268-z","article-title":"Immune reconstitution therapies: concepts for durable remission in multiple sclerosis","volume":"16","author":"L\u00fcnemann","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0530","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.04.001_bib0535","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.04.001_bib0540","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40263-025-01182-8","article-title":"The evolution of anti-CD20 treatment for multiple sclerosis: optimization of antibody characteristics and function","volume":"39","author":"Cree","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurol.2026.04.001_bib0545","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","article-title":"Progressive multiple sclerosis: from pathophysiology to therapeutic strategies","volume":"18","author":"Faissner","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.neurol.2026.04.001_bib0550","first-page":"CD015443","article-title":"Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis","volume":"9","author":"Ridley","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2026.04.001_bib0555","doi-asserted-by":"crossref","first-page":"e209886","DOI":"10.1212\/WNL.0000000000209886","article-title":"Anti-CD20 therapies in drug-naive patients with primary progressive multiple sclerosis: a multicenter real-life study","volume":"103","author":"Hay","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.04.001_bib0560","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0565","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00415-025-12892-w","article-title":"Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn","volume":"272","author":"Robertson","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0570","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/WCO.0000000000001363","article-title":"Update on novel multiple sclerosis treatments: from dismal defeat to scintillating success","volume":"38","author":"Cree","year":"2025","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0575","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.04.001_bib0580","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0585","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.04.001_bib0590","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11940-024-00818-2","article-title":"Inhibiting CD40 ligand in multiple sclerosis: a review of emerging therapeutic potential","volume":"27","author":"Vermersch","year":"2024","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0595","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/brain\/awx372","article-title":"Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells","volume":"141","author":"Smets","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.04.001_bib0600","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.193.8.967","article-title":"The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system","volume":"193","author":"Becher","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurol.2026.04.001_bib0605","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/path.5205","article-title":"Macrophage CD40 signaling drives experimental autoimmune encephalomyelitis","volume":"247","author":"Aarts","year":"2019","journal-title":"J Pathol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0610","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2017.01.024","article-title":"Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"305","author":"Masuda","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0615","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1468-1331.2001.00232.x","article-title":"Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis","volume":"8","author":"Jensen","year":"2001","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2026.04.001_bib0620","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with frexalimab in multiple sclerosis","volume":"390","author":"Vermersch","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2026.04.001_bib0625","doi-asserted-by":"crossref","first-page":"13765","DOI":"10.1002\/anie.201407807","article-title":"A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis","volume":"53","author":"Hern\u00e1ndez-Torres","year":"2014","journal-title":"Angew Chem"},{"key":"10.1016\/j.neurol.2026.04.001_bib0630","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1038\/s41467-023-43606-3","article-title":"A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.neurol.2026.04.001_bib0635","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40263-025-01182-8","article-title":"The evolution of anti-CD20 treatment for multiple sclerosis: optimization of antibody characteristics and function","volume":"39","author":"Cree","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurol.2026.04.001_bib0640","doi-asserted-by":"crossref","first-page":"e200208","DOI":"10.1212\/NXI.0000000000200208","article-title":"Safety and dose-response of vidofludimus calcium in relapsing multiple sclerosis: extended results of a placebo-controlled phase 2 trial","volume":"11","author":"Fox","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:15:12Z","timestamp":1792674912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726005072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0035378726005072"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.04.001","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New immunotherapies for multiple sclerosis (MS): A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}